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SUMMARY
Overactive bladder syndrome (OAB) is a chronic condi-
tion characterised by urgency, with or without associated
urge incontinence. Solifenacin succinate is a once daily,
bladder selective antimuscarinic available in two doses (5
and 10 mg). The recommended dose is 5 mg once daily
and can be increased to 10 mg once daily if 5 mg is well
tolerated. This article presents pooled efﬁcacy and safety
data from four large, placebo-controlled, multinational
phase III trials of solifenacin succinate with a total enrol-
ment of over 2800 patients. Data from these trials show
that solifenacin 5 and 10 mg once daily is signiﬁcantly
more effective than placebo at reducing urgency, incon-
tinence, micturition frequency and nocturia and at
increasing volume voided per micturition. Adverse events
were mainly mild-to-moderate in all treatment groups.
The results of these phase III trials support the use of
solifenacin in the treatment of OAB.
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INTRODUCTION
Overactive bladder syndrome (OAB) is deﬁned by the Inter-
national Continence Society (ICS) as urgency, with or with-
out urge incontinence, usually with frequency and nocturia
(1). As such, it is a symptomatic diagnosis acknowledging
the presence of storage symptoms, based on a patient’s his-
tory alone, which is suggestive of urodynamically demon-
strable detrusor overactivity, in the absence of proven
infection or obvious pathology (1). In deﬁning OAB and
considering the individual components comprising this
symptom complex, the ICS has highlighted the signiﬁcant
role of urgency (1). Urgency is important as it is thought to
play a pivotal role in driving the other symptoms of OAB
(urinary incontinence, frequency and nocturia) (2). As illus-
trated in Figure 1, urgency is thought to cause these other
OAB symptoms by reducing the time that voiding can be
deferred, thereby increasing micturition frequency and redu-
cing the volume voided per micturition. Urgency is also
thought to contribute to incontinence and nocturia, but the
relationship is less direct (2).
Bladder storage symptoms have a severe impact on all
areas of quality of life (QoL) including social, psychological
and work function (3,4). Therapy for chronic, non-life
threatening conditions, such as OAB, should focus on
patient beneﬁt and in doing so must take account of patient
perceived outcomes, rather than simple symptom resolution
alone. Efﬁcacy of OAB therapy needs to be balanced against
tolerability, as a low incidence of adverse events (AEs)
improves compliance with treatment. This balance between
efﬁcacy and tolerability should provide palpable beneﬁts
from a patient’s perspective, and promote persistence with a
therapy, which is of course an important issue in chronic
conditions, such as OAB, that require continued therapy.
Unfortunately, many antimuscarinics, especially older agents,
have modest clinical efﬁcacy and are associated with unfa-
vourable side effects, leading to poor persistence with therapy
(5). Many clinical trials of antimuscarinics have not pub-
lished efﬁcacy endpoints for all the symptoms contained
within the ICS deﬁnition for OAB and, further, often over-
look patient beneﬁts such as treatment satisfaction and QoL.
Antimuscarinic agents are the mainstay of OAB pharma-
cotherapy, and exert their effects by competitively blocking
acetylcholine binding at the muscarinic receptors within the
various histological compartments of the bladder. As well as
being released from efferent cholinergic nerves innervating
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acetylcholine can be released by stretch of the urothelium
from non-neuronal sources, in addition to being related to
leakage from neurones (6). There is also increasing evidence
that acetylcholine may act on receptors in the suburothelial
plexus, thereby inﬂuencing the afferent system and detrusor
contraction.
Solifenacin succinate is a once-daily, oral antimusarinic
agent, which shows in vitro selectivity for bladder tissue over
salivary preparations (7,8). Solifenacin has also displayed
efﬁcacy in the treatment of OAB, as demonstrated in four
large double-blind, placebo-controlled, 12-week, phase III
studies assessing over 3000 patients (9–12). As protocols
were similar, we are able to present the pooled data from
these four studies, allowing an objective evaluation of the
efﬁcacy and tolerability of once-daily solifenacin 5 and
10 mg in reducing all symptoms of OAB in one of the lar-
gest pooled analyses of an antimuscarinic agent to date.
MATERIALS AND METHODS
Study design and protocol
Four multinational, double-blind, randomised, phase III
studies were conducted with similar protocols (9–12). A tol-
terodine 2 mg twice daily active treatment arm was included
in one of the four studies, but was not powered for compar-
ison. The methods, design and results of this single study
have been previously published (10); the tolterodine data
are excluded from the pooled analysis in this current report
(Figure 2).
Patients completed a 3-day micturition diary before the
ﬁrst visit and before all subsequent monthly visits. All
patients underwent a baseline assessment including medica-
tion history, physical examination, vital signs, laboratory
tests and electrocardiogram. After completing a 2-week pla-
cebo run-in or screening/washout period, patients began
their treatment regimen on the ﬁrst day of the study. In
two of the studies, patients were randomised to once-daily
treatment with solifenacin 10 mg or placebo. In the other
two studies, patients were randomised to once-daily treat-
ment with 5 mg solifenacin, 10 mg solifenacin or placebo.
These studies were performed in accordance with the
International Conference on Harmonisation Good Clinical
Practice guidelines, and the principles of the Declaration of
Helsinki. The study protocol was approved by the respon-
sible ethical committee at each study site. All patients were
informed of the nature and purpose of the study, and writ-
ten informed consent was obtained before screening.
Patients
Outpatient men and women, at least 18 years of age, with
symptoms of OAB were eligible for enrolment. During a
baseline 3-day micturition diary period, patients were
required to report a mean of  8 micturitions per 24 h, and
either a mean of  1 incontinence episode per 24 h or a
mean of  1 urgency episode per 24 h.
Efﬁcacy analysis
Data on urgency, incontinence, micturition frequency,
nocturia episodes and volume voided were collected using a
3-day micturition diary, and reported at baseline and before
visits at weeks 4, 8 and 12. For each episode, date and time,
whether or not the patient voided, the presence of urgency
and incontinence, volume voided (for at least 2 of the
3 days), and whether or not the episode disturbed the
patient’s sleep (episodes of nocturia) were recorded; the time
of rising from and going to bed were also recorded. Efﬁcacy
analyses included mean and median changes from baseline
to endpoint in the number of each of the following per
24 h: episodes of urgency, incontinence, nocturia and
micturitions. The volume voided per micturition was also
Figure 1 The role of urgency in initiating overactive bladder
syndrome symptoms (reproduced from Chapple et al. 2005 –
permission requested (2))
Figure 2 Study design. n ¼ number of patients evaluated for
efﬁcacy; od ¼ once daily. The tolterodine treatment arm was
included in only one of the four phase III studies
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assessment were excluded from the analyses. In line with
ICS guidelines for the presentation of data, symptom ‘reso-
lution’/’normalisation’ rates were also examined, as well as
an assessment of the 50% improvement in the symptoms of
urgency, incontinence, number of micturitions and nocturia
(13). Symptom ‘resolution’ was deﬁned as the complete
absence of symptoms at the study endpoint that were pre-
sent at baseline. Symptom ‘normalisation’ applied only to
micturition frequency, and was deﬁned as a reduction to
below eight micturitions per 24 h.
Two of the four trials described in this analysis measured
QoL changes using the King’s Health Questionnaire
(KHQ) (14). Solifenacin signiﬁcantly improved KHQ scores
from baseline in nine of 10 domains compared with pla-
cebo, demonstrating statistically signiﬁcant improvements in
patient QoL (15,16). The clinical relevance of improve-
ments in the KHQ scores was determined using a scale
based on a global rating of patient-perceived treatment
beneﬁt, and perceived disease impact (25): a minimally
important difference (MID) was deﬁned as a 15% point
change from baseline, which focussed on the differences
between the solifenacin- and placebo-treatment groups for
each individual KHQ domain.
Safety assessments
Treatment emergent adverse events (TEAEs) were evaluated
for the safety population. A TEAE was deﬁned as an AE
that occurred after the ﬁrst dose of study medication that
was not evident before treatment, or worsening of an AE
that was present before start of treatment. Treatment-emer-
gent adverse events were classiﬁed into mild/moderate and
severe groups, as determined by the investigator. Serious
AEs were reported based on the International Conference
on Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use (ICH) criteria. Dis-
continuation rates due to AEs were also evaluated.
Statistical methods
Mean changes from baseline to endpoint in all symptoms
were compared by analysis of covariance (ANCOVA) for each
OAB outcome, with treatment and centre as terms and
baseline as a covariate. Treatment group comparisons of
‘responder’ or ‘normalisation’ rates were based on Fisher’s
exact test. Actual mean change from baseline to endpoint
was normally distributed; therefore, p-values were based on
the ANCOVA model. The percent change from baseline to
endpoint was not normally distributed; therefore, p-values
for the percent change were based on Van Elteren’s test
stratiﬁed by pooled centre. Endpoint was deﬁned as the last
available on-treatment assessment. The p-values for the pair-
wise testing of solifenacin vs. placebo differences in MID
for KHQ changes were based on a logistic regression model




Baseline characteristics and OAB symptoms for the pooled
study population are summarised in Table 1. From a total
of 3032 patients randomised to 5 mg solifenacin, 10 mg
solifenacin or placebo, data from 2848 patients were avail-
able for the analysis of efﬁcacy and was deﬁned as the full
analysis set (Figure 2). Of the patients included in the pre-
sent analysis, 99% of patients reported an urgency episode,
66% reported an incontinence episode and 89% reported a
Table 1 Baseline demographics and efﬁcacy characteristics for the full analysis set
Placebo Solifenacin 5 mg od Solifenacin 10 mg od
Number of subjects (n) 1138 552 1158
Age (years)
Mean 58.0 56.7 57.9
065 years, n (%) 742 (65) 370 (67) 756 (65)
 65 years, n (%) 396 (35) 182 (33) 402 (35)
Gender
Male (%) 219 (19) 121 (22) 242 (21)
Female (%) 919 (81) 431 (78) 916 (79)
Baseline OAB symptom levels, mean (SE)
Urgency episodes per 24 h (n ¼ 2823) 6.3 (0.12) 5.9 (0.20) 6.2 (0.12)
Incontinence episodes per 24 h (n ¼ 1873) 2.9 (0.10) 2.6 (0.14) 2.9 (0.10)
Micturitions per 24 h (n ¼ 2848) 11.9 (0.11) 12.1 (0.16) 11.9 (0.10)
Volume voided per micturition (ml) (n ¼ 2843) 165.5 (2.24) 149.0 (2.30) 163.4 (2.08)
Nocturia episodes per 24 h (n ¼ 2534) 1.8 (0.04) 2.0 (0.05) 1.8 (0.04)
od, once daily; OAB, overactive bladder syndrome; SE, standard error of mean.
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part of the inclusion criteria, all patients had a micturition
frequency of  8 micturitions per day.
Improvements in overactive bladder symptoms
Changes from baseline to endpoint in urgency, incontin-
ence, micturition frequency, volume voided and nocturia
are summarised in Table 2. Compared with placebo, solif-
enacin treatment at either the 5 or 10 mg dose resulted in a
signiﬁcant improvement in all of the symptoms measured.
This was statistically signiﬁcant for both 5 and 10 mg solif-
enacin doses, when comparing mean actual reductions for
all of the OAB symptoms and for the mean actual increase
in volume voided per micturition (Table 2). When assessing
urgency (mean absolute values and median percentage val-
ues), treatment with solifenacin 5 and 10 mg resulted in a
)2.9 ()66.1%) and )3.4 ()70.0%) baseline to endpoint
reduction in urgency episodes, respectively, compared with
a )2.0 ()40.0%) episode reduction in patients receiving
placebo (p 0 0.001 for both solifenacin doses vs. placebo).
The reduction in incontinence for 5 and 10 mg solifenacin
was )1.5 ()100%) and )1.8 ()100%) baseline to endpoint
reduction in episodes compared with a )1.1 ()63.6%) epi-
sode reduction for patients receiving placebo (p 0 0.001
for both doses vs. placebo). The frequency of micturition
was signiﬁcantly reduced in patients receiving both solifena-
cin 5 mg ()2.3; )19.4%) and 10 mg ()2.7; )22.5%),
compared with placebo ()1.4; )12.0%; p 0 0.001 for
both doses); this was reﬂected in the number of nocturia
episodes, which were also reduced signiﬁcantly in solifenacin
5 mg recipients ()0.6; )35.5%) and 10 mg recipients
()0.6; )36.4%), compared with patients receiving placebo
()0.4; )25.0%; p 0 0.05 and 00.001 for solifenacin 5
and 10 mg, respectively). In addition, the volume voided
per micturition increased signiﬁcantly after solifenacin treat-
ment, both with 5 mg (32.3 ml; 19.0%) and 10 mg
(42.5 ml; 25.7%), compared with treatment with placebo
(8.5 ml; 3.1%; p 0 0.001 for both doses) (Figure 3). The
greater efﬁcacy seen with solifenacin at both doses, com-
pared with placebo was not affected by either age or gender
(Table 2).
‘Resolution’/‘normalisation’ rates and ‡50%
improvements from baseline
In patients treated with solifenacin 5 and 10 mg who had
urgency at baseline, 29% and 25%, respectively, had no
urgency episodes at endpoint when compared with placebo
(15%). This difference was statistically signiﬁcant for both
doses of solifenacin (p 0 0.001) (Table 3). Furthermore, of
those patients who had incontinence at baseline, 51% and
52% of patients receiving 5 and 10 mg solifenacin, respect-
ively, reported no incontinence episodes at the study end-
point, compared with only 34% of patients receiving
placebo (p 0 0.001; Table 3). Patients treated with either
solifenacin dose also experienced normalisation of mictur-
ition frequency, which was statistically signiﬁcantly greater
than placebo (p 0 0.001 for both solifenacin dose groups;
Table 3). Similar results were seen with respect to resolution
Table 2 Mean actual change in overactive bladder syndrome symptoms from baseline to endpoint












n Change n Change n Change n Change n Change
Placebo (total) 1124 )2.0 781 )1.1 1138 )1.4 1135 8.5 1005 )0.4
Placebo (065 years) 733 )2.2 494 )1.2 742 )1.6 739 8.2 640 )0.5
Placebo ( 65 years) 391 )1.6 287 )1.0 396 )1.1 396 9.1 365 )0.3
Placebo (males only) 217 )1.9 94 )0.7 219 )1.2 219 )0.9 194 )0.4
Placebo (females only) 907 )2.0 687 )1.2 919 )1.5 916 10.8 811 )0.4
Solifenacin 5 mg (total) 548 )2.9 314 )1.5 552 )2.3 552 32.3 494 )0.6*
Solifenacin 5 mg (065 years) 366 )2.8 208 )1.6 370 )2.5 370 33.4 326 )0.6
Solifenacin 5 mg ( 65 years) 182 )3.2 106 )1.5* 182 )2.0 182 30.2 168 )0.6
Solifenacin 5 mg (males only) 121 )2.7* 43 )1.7 121 )1.9* 121 25.7 109 )0.5
Solifenacin 5 mg (females only) 427 )3.0 271 )1.5 431 )2.4 431 34.2 385 )0.6*
Solifenacin 10 mg (total) 1151 )3.4 778 )1.8 1158 )2.7 1156 42.5 1035 )0.6
Solifenacin 10 mg (065 years) 753 )3.5 482 )1.7 756 )2.8 755 40.5 666 )0.6*
Solifenacin 10 mg ( 65 years) 398 )3.2 296 )1.9 402 )2.5 401 46.2 369 )0.5*
Solifenacin 10 mg (males only) 242 )3.2 111 )1.6* 242 )2.5 242 32.7 212 )0.4
Solifenacin 10 mg (females only) 909 )3.4 667 )1.8 916 )2.8 914 45.1 823 )0.6
*p 0 0.05 vs. placebo; p 0 0.001 vs. placebo.
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signiﬁcant resolution of symptoms compared with placebo.
In line with ICS guidelines for the presentation of data (1),
the  50% improvement rates (i.e. the per cent of patients
who achieved  50% improvement in symptoms that were
present at baseline) are provided in Table 4. The per cent
of solifenacin-treated patients achieving a  50% reduction
in symptoms was signiﬁcantly greater than placebo for
urgency, incontinence, frequency and nocturia.
Achievement of a minimally important difference
in quality of life from baseline
In the two studies which examined QoL data, solifenacin
signiﬁcantly improved KHQ scores from baseline in nine
of 10 domains compared with placebo, demonstrating sta-
tistically signiﬁcant improvements in patient QoL (15,16).
When the MID was examined for each of the individual
KHQ domains, it was shown that a signiﬁcantly greater
percentage of patients receiving solifenacin achieved an
MID in certain individual domains than those receiving
placebo [solifenacin 5 mg: general health perception,
incontinence impact, role limitations, social limitations,
emotions, sleep/energy, severity measures and symptom
severity; p 0 0.05 vs. placebo; solifenacin 10 mg: general
health perception, incontinence impact, role limitations,
physical limitations, social limitations, emotions, sleep/
energy, severity measures and symptom severity; p 0 0.05
vs. placebo (Figure 4)].
Figure 3 Median per cent changes in
overactive bladder syndrome symptoms
from baseline to endpoint. *p 0 0.05 vs.
placebo; p 0 0.001 vs. placebo.
p-values for the per cent change from
baseline are based on the Van Elteren’s
test. od ¼ once daily










% n (N) % n (N) % n (N) % n (N)
Placebo 15.5 174 (1124) 34.1 266 (781) 22.4 255 (1138) 14.5 146 (1005)
Solifenacin 5 mg 28.6 157 (548) 50.6 159 (314) 33.0 182 (552) 16.2 80 (494)
Solifenacin 10 mg 25.5 293 (1151) 51.8 403 (778) 37.3 432 (1158) 19.0 197 (1036)
*Resolution is deﬁned as an absence of the symptom at endpoint; p 0 0.01 vs. placebo; p 0 0.001 vs. placebo; n, number of patients achieving ‘resolu-
tion’/‘normalisation’; N, number of patients with speciﬁed overactive bladder syndrome symptom at baseline assessment.
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Treatment was well tolerated with both doses of solifenacin,
with the majority of AEs being mild-to-moderate in nature.
The most common TEAEs were dry mouth, constipation,
and blurred vision, all of which are recognised side effects
of antimuscarinic therapy (Table 5). Although the incidence
of dry mouth was higher in the 10 mg solifenacin treated
group compared with patients receiving 5 mg solifenacin,
the number of patients discontinuing treatment due to AEs
was low and comparable with placebo at both solifenacin
doses (4.4% placebo, 2.8% solifenacin 5 mg, 6.8% solifena-
cin 10 mg). Completion rates in the studies were also high
(86.4% placebo, 91.0% solifenacin 5 mg, 86.7% solifenacin
10 mg).
DISCUSSION
Overactive bladder syndrome is a chronic condition encom-
passing the bothersome storage symptoms of urgency, with
or without urge incontinence, usually with frequency and
nocturia. Therefore, effective treatment of OAB must result
in a reduction meaningful to the patient in all of these
symptoms. This review of the data clearly shows that treat-
ment with once-daily solifenacin 5 and 10 mg is associated
with signiﬁcant improvements in all of the symptoms of
OAB. Indeed, 125% of solifenacin-treated patients experi-
enced resolution of urgency, 150% of solifenacin-treated
patients achieved continence, and at least one-third of solif-
enacin-treated patients experienced ‘normalisation’ of mic-
turition frequency to eight or fewer voids per day by study
Table 4 Patients achieving a  50% reduction in overactive bladder syndrome symptoms
Urgency episodes Incontinence episodes Micturitions Nocturia episodes
% n (N) % n (N) % n (N) % n (N)
Placebo 43.8 492 (1124) 57.6 450 (781) 43.5 495 (1138) 36.2 364 (1005)
Solifenacin 5 mg 61.9 339 (548) 70.7 222 (314) 60.5 334 (552) 43.3%* 214 (494)
Solifenacin 10 mg 66.2 762 (1151) 78.5 611 (778) 63.6 736 (1158) 43.6 452 (1036)
*p 0 0.01 vs. placebo; p 0 0.001 vs. placebo. n, number of patients achieving ‘resolution’/‘normalisation’; N, number of patients with speciﬁed overactive
bladder syndrome symptom at baseline assessment. p-values for between-treatment comparisons of ‘responder’ and ‘normalisation’ rates were based on Fish-
er’s exact test.
Figure 4 Percentage of subjects achieving a clinically meaningful minimally important difference (MID) ( 5 points) in King’s Health
Questionnaire individual domain scores (mean change from baseline to end of study). *p 0 0.05; p   0.001 vs. placebo using a logistic
regression model. od ¼ once daily; MIDs based on Reese et al. (25)
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well tolerated by patients, with a few discontinuations due
to AEs. If one acknowledges the importance of urgency as a
pivotal symptom in this symptom complex; then clearly the
high resolution and improvement rates may well be due to
solifenacin’s impact on the key symptom of urgency (2).
Clearly, pharmacotherapy for OAB should not only
improve symptoms, but also be tolerable, both of which will
contribute to treatment persistence. One very effective meas-
ure of this ‘clinical effectiveness’ is assessment of QoL. Two
of the four trials described in this analysis measured QoL
changes (10,12), using the KHQ (14). Solifenacin signiﬁ-
cantly improved KHQ scores from baseline in nine of 10
domains compared with placebo, demonstrating statistically
signiﬁcant improvements in patient QoL (15,16). The
clinical relevance of these improvements to patients was
determined using a scale based on a global rating of patient-
perceived treatment beneﬁt, and perceived disease impact
(15,16). When using the following deﬁnition of clinical
meaning: MID   5 percentage point change from baseline;
it was shown that patients who were treated with both 5 and
10 mg solifenacin demonstrated a statistically signiﬁcant and
clinically meaningful MID improvement from baseline in
almost all KHQ domains, compared with patients receiving
placebo. These improvements in QOL are likely to have
contributed to the high persistence rates with solifenacin des-
cribed in the present analysis (approximately 90% for
patients receiving solifenacin). Similarly, high persistence
rates have also been observed with longer-term treatment
with solifenacin. In a 40-week, open-label extension of two
of the studies included in this analysis, 81% of patients
remained on solifenacin treatment for the full treatment per-
iod (17). Furthermore, patient satisfaction with treatment
efﬁcacy and tolerability was high (74% and 85%, respect-
ively) when assessed at the end of the extension study (17).
The differences in the methodology used to record efﬁcacy
data (e.g. different study populations, different inclusion and
exclusion criteria, different ways to measure and deﬁne
urgency, and varying diary durations) and the selective pres-
entation of data for symptom reduction, make it difﬁcult
and indeed academically questionable whether one can com-
pare the results presented here with those of other published
clinical trials. However, globally allowing for these mis-
givings, solifenacin appears to compare favourably to other
antimuscarinics with respect to treating urgency and all of
the other symptoms of OAB (18–21). This drug is the ﬁrst
antimuscarinic for which there are published reports of
improvements in all the key symptoms of OAB – frequency,
urgency, incontinence and nocturia. Other publications of
pivotal trial data for other antimuscarinic agents have repor-
ted data for some, but not all, of these symptoms (18–21).
When considering the current published literature, there
are few data available that report the ‘normalisation’ rates
for OAB symptoms (18–21). Most reports only provide this
information for incontinence rates and do not present sim-
ilar results for the proportion of patients who achieve cessa-
tion of urgency and nocturia, or normalisation of
micturition frequency (08 micturitions per 24 h). Sympto-
matic outcome measures such as this should be considered
to be an essential facet of the assessment of treatment efﬁ-
cacy and should, therefore, be of keen interest to both clini-
cians and other healthcare providers in determining the
clinical effectiveness and utility of different antimuscarinics.
In conclusion, solifenacin’s efﬁcacy has clearly been dem-
onstrated in published studies for all symptoms of the OAB
complex, with a high degree of tolerability and patient
beneﬁt. Whilst it is interesting to speculate that the symp-
tom improvements may be driven by the favourable impact
that solifenacin has on urgency, clearly, further studies using
more accurate measures of patient perceived outcome are
necessary to compare this agent to other antimuscarinics.
Recently published results from the STAR study have provi-
ded a head-to-head comparison between solifenacin and tol-
terodine ER (22,23). This study suggested that ﬂexible
dosing with both 5 and 10 mg solifenacin is more effective
in reducing OAB symptoms such as urgency, incontinence,
urge incontinence and improving volume voided, as well as
improving patient perception of bladder condition, when
compared with the highest (and recommended) dose of tol-
terodine ER (4 mg). The ﬂexibility associated with solifena-
cin dosing may further increase its efﬁcacy, as well as
allowing treatment regimens to be designed for the needs of
the individual patient, thus improving patient compliance
and satisfaction (24). Although the occurrence of common
antimuscarinic AEs was greater with solifenacin-treated
patients than with tolterodine-treated patients, the rate of
patient discontinuation was low with solifenacin use, and
comparable with tolterodine (23), due to the high rate of
Table 5 Rates of dry mouth, constipation and blurred vision,










Mild/moderate 50 4.1 62 10.7 323 26.2
Severe 1 0.1 1 0.2 19 1.5
Constipation
Mild/moderate 35 2.9 30 5.2 151 12.2
Severe 0 0 1 0.2 15 1.2
Blurred vision
Mild/moderate 22 1.8 21 3.6 56 4.5
Severe 0 0 1 0.2 4 0.3
Discontinuation due
to all adverse events*
53 4.4 16 2.8 84 6.8
*Adverse events were given as the primary reason for discontinuation.
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long-term use of solifenacin (17). Further head-to-head
comparison studies with other antimuscarinic OAB therap-
ies are needed before deﬁnitive conclusions can be drawn.
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